Today announced it provides initiated a Phase I/II dose-escalating research of its proprietary.

Thiarabine is usually a novel nucleoside analog with significant potential for the treatment of cancer. Great interest has been shown in this course of molecules. Three nucleoside analogs have been approved in recent years and extensive research continues to produce substances with improved activity. In preclinical versions, Thiarabine has exhibited significant activity, including cures or regressions, in six leukemia or lymphoma cell lines.This article is definitely republished with kind permission from our friends at The Kaiser Family Foundation. You can view the complete Kaiser Daily Health Policy Statement, search the archives, or sign up for email delivery of in-depth coverage of health policy developments, discussions and debates. The Daily Health Policy Report is published for, a free of charge support of The Henry J. Kaiser Family Foundation. Copyright 2009 Advisory Board Business and Kaiser Family Basis. All rights reserved.

325,000 pounds frozen meat recalled over Listeria Meatball-maker Buona Vita, Inc.